NEUROPSYCHIATRIC DISORDERS TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)
Segmentation
By DisorderMajor Depressive Disorder · Bipolar Disorder · Anxiety Disorders · Schizophrenia Spectrum Disorders · Trauma- and Stressor-Related Disorders · Obsessive-Compulsive and Related Disorders · Attention-Deficit/Hyperactivity Disorder · Autism Spectrum Disorder · Substance Use Disorders · Sleep-Wake Disorders · Neurocognitive Disorders · Movement Disorders with psychiatric symptom control · Eating Disorders · and Personality Disorders
By Drug ClassAntidepressants · Antipsychotics · Mood Stabilizers · Anxiolytics and Sedative-Hypnotics · ADHD Medications · Cognitive Enhancers · Substance Use Disorder Medications · Movement and Impulse Control Agents · and Adjunctive Symptom-Control Agents
By Route of AdministrationOral · Parenteral · Intranasal · Transdermal · and Sublingual or Buccal
By Molecule TypeSmall molecules · Biologics · and Combination drugs (fixed-dose combinations) · By Formulation Type (Immediate release, Extended release or controlled release, Long-acting depot formulations, Orally disintegrating formulations, Liquid oral formulations, and Prodrug formulations) · By Patient Age Group (Pediatric, Adolescent, and Adult/Geriatric) · By Care Setting (Inpatient, Outpatient, Community-based Care, Home-based Care, and Telehealth and Virtual Care) · By Provider Type (Psychiatrists, Neurologists, Primary Care Physicians, Psychologists and Therapists, Addiction Medicine Specialists, and Integrated Care Teams) · By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) · By Payment Type (Public and Private) · By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
Published In01 Apr 2026
Report CodeCMI9127
Pages250+
FormatsExcel and PDF
Base Year2025
Estimated Year2026
Historical Range2020 - 2024
Forecast Period2026-2033
Market Segmentation
Disorder Insights (Revenue, USD Bn, 2021 - 2033)
Major Depressive Disorder
Bipolar Disorder
Anxiety Disorders
Schizophrenia Spectrum Disorders
Trauma- and Stressor-Related Disorders
Obsessive-Compulsive and Related Disorders
Attention-Deficit/Hyperactivity Disorder
Autism Spectrum Disorder
Substance Use Disorders
Sleep-Wake Disorders
Neurocognitive Disorders
Movement Disorders with psychiatric symptom control
Eating Disorders
Personality Disorders
Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
Antidepressants
Antipsychotics
Mood Stabilizers
Anxiolytics and Sedative-Hypnotics
ADHD Medications
Cognitive Enhancers
Substance Use Disorder Medications
Movement and Impulse Control Agents
Adjunctive Symptom-Control Agents
Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
Oral
Parenteral
Intranasal
Transdermal
Sublingual or Buccal
Molecule Type Insights (Revenue, USD Bn, 2021 - 2033)
Small molecules
Biologics
Combination drugs (fixed-dose combinations
Formulation Type Insights (Revenue, USD Bn, 2021 - 2033)
Immediate release
Extended release or controlled release
Long-acting depot formulations
Orally disintegrating formulations
Liquid oral formulations
Prodrug formulations
Patient Age Group Insights (Revenue, USD Bn, 2021 - 2033)
Pediatric
Adolescent
Adult/Geriatric
Care Setting Insights (Revenue, USD Bn, 2021 - 2033)
Inpatient
Outpatient
Community-based Care
Home-based Care
Telehealth and Virtual Care
Provider Type Insights (Revenue, USD Bn, 2021 - 2033)
Psychiatrists
Neurologists
Primary Care Physicians
Psychologists and Therapists
Addiction Medicine Specialists
Integrated Care Teams
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Payment Type Insights (Revenue, USD Bn, 2021 - 2033)
